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PERSPECTIVEIncreasing Comorbidities Suggest that Atopic
Dermatitis Is a Systemic Disorder
Patrick M. Brunner1, Jonathan I. Silverberg2, Emma Guttman-Yassky3, Amy S. Paller2,
Kenji Kabashima4, Masayuki Amagai5, Thomas A. Luger6, Mette Deleuran7, Thomas Werfel8,
Kilian Eyerich9 and Georg Stingl10, Councilors of the International Eczema CouncilAtopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma,
allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic
immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema
Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and
systemic infections. Associations with cardiovascular, neuropsychiatric, and malignant diseases were increas-
ingly reported, but confirmation of their link with atopic dermatitis requires longitudinal studies. Given the
possibility of atopic dermatitis-related systemic immune activation, future investigations of new interventions
should concurrently examine the impact on these comorbidities.
Journal of Investigative Dermatology (2017) 137, 18e25; doi:10.1016/j.jid.2016.08.022INTRODUCTION
The immune-mediated skin disease
atopic dermatitis (AD) has long been
recognized as closely associated with
other atopic conditions. More recent
studies have uncovered multiple previ-
ously unrecognized disease associa-
tions, further highlighting the possibility
that AD is a systemic disorder. Coun-
cilors of the International Eczema
Council, all leaders in AD research,
gathered at the Annual European
Society for Dermatological Research
meeting in 2015 to review the increas-
ingly recognized comorbidities,
including controversial associations,
that may contribute to the burden
of AD.
Before the meeting, presenters
searched for AD/eczema studies from
2000 through 2016 using PubMed,
Google scholar, Science direct, and
ClinicalTrials.gov using keywords such
as atopic dermatitis or eczema com-
bined with infection, cardiovascular,1The Laboratory for Investigative Dermatology, The R
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Topics were then discussed by the
group, and teams of Councilors further
reviewed the literature from
2000e2016 literature to describe (i)
pathogenic concepts of immune acti-
vation leading to both overt inflamma-
tion and increased susceptibility to
infection in AD and (ii) associations
with AD derived from epidemiologic
studies, in which pathogenic mecha-
nisms are still largely unclear. Selected
effects sizes of disease associations for
autoimmune, infectious, cardiovascu-
lar, malignant, and neuropsychiatric
disorders are summarized in
Supplementary Table S1 online.
ATOPIC DERMATITIS AND SYSTEMIC
IMMUNE DEVIATION
The atopic march
AD usually begins early in life
(Czarnowicki et al., 2015a; Eichenfield
et al., 2012), and its onset is often
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atopic march, especially food al-
lergies, asthma, and allergic rhino-
conjunctivitis (Schneider et al., 2016;
Simpson et al., 2012). This sequence
has recently been challenged, sug-
gesting that developmental profiles
might be much more heterogeneous
(Belgrave et al., 2014). AD patients,
often in adulthood, also suffer from
increased frequencies of hand eczema
and allergic contact dermatitis
(Thyssen et al., 2010, 2014), although
these conditions are not classically
included as components of the atopic
march.
Allergic sensitization may result
from skin barrier dysfunction, facili-
tating cutaneous allergen penetration.
Loss-of-function mutations in the gene
encoding filaggrin, FLG, are associated
with an increased risk of AD and
asthma (Irvine et al., 2011; McAleer
and Irvine, 2013) and are present in
15e46% of AD patients (Brown et al.,epartment of Dermatology, Northwestern
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helper (Th) 2 (IL-4/IL-13/IL-25) and
Th22 (IL-22) cytokines, which are
increased in AD, suppress filaggrin
expression in keratinocytes (Gutowska-
Owsiak et al., 2011; Howell et al.,
2007; Hvid et al., 2011; Pellerin
et al., 2013) and may contribute to
the barrier deficits in vivo. Thus, im-
mune activation in AD may trigger
barrier dysfunction and/or aggravate
inherited barrier defects through a
positive feedback loop (Leung and
Guttman-Yassky, 2014). Subsequent
migration of sensitized T cells and/or
IgE into the nose and airways facilitates
upper and lower airway disease (Kubo
et al., 2012; Leung, 2013). The
important role of barrier defects in AD
has further justified vigorous applica-
tion of emollients, which likely
contribute more than barrier substitu-
tion, given that petrolatum application
increases expression of barrier proteins
and antimicrobial peptides and de-
creases proinflammatory cytokines
(Czarnowicki et al., 2016). Further-
more, preliminary studies suggest that
proactive application of emollients to
infants at risk for AD, beginning as
neonates, reduces AD development
and/or severity (Horimukai et al.,
2014; Simpson et al., 2014). Longitu-
dinal studies are currently addressing
the ability of early emollient applica-
tion to decrease sensitization to anti-
gens and development of the atopic
march.
A recent mechanistic study sug-
gested that Th2/Th22 skewing and
epidermal hyperplasia, but not the
deficiency of barrier proteins of adult
AD, are seen in the skin of infants and
toddlers with new-onset disease, sug-
gesting an early role for T-cell skewing
(Esaki et al., 2016). Nevertheless, the
correlation of high transepidermal
water loss at 2 days of age and the
occurrence of AD at 1 and 2 years of
age suggest an early barrier defect as
an initial driver (Kelleher et al., 2015;
Kelleher et al., 2016). Additional
studies in infants and children are
warranted to address potential differ-
ences between infant/childhood (i.e.,
early-onset) and adult (i.e., chronic)
disease to better understand disease
evolution with age and disease
heterogeneity (Garmhausen et al.,
2013).Immune activation beyond the skin
Similar to psoriasis, AD skin lesions are
accompanied by epidermal hyperpla-
sia, large T-cell and dendritic cell in-
filtrates, and increased production of
inflammatory products (Guttman-
Yassky et al., 2011a, 2011b). Psoriasis
has been associated with inflammation
in several noncutaneous systems,
particularly the joints, gastrointestinal,
and cardiovascular systems, and eleva-
tions in C-reactive protein are associ-
ated with disease severity (Beygi et al.,
2014). In contrast to psoriasis, how-
ever, AD immune abnormalities also
profoundly involve nonlesional skin
and the blood compartment (Leung and
Guttman-Yassky, 2014; Suarez-Farinas
et al., 2011; Tang et al., 2014),
although acute phase reactants, such as
C-reactive protein, do not tend to be
elevated. These observations suggest
that the mechanisms of the inflamma-
tory component of AD and psoriasis are
different. Indeed, blood from in-
dividuals with AD has more polar dif-
ferentiation of central and effector
memory T-cell subsets and significantly
higher and more persistent T-cell acti-
vation than is seen in psoriasis
(Czarnowicki et al., 2015b, 2015c).
Ongoing blood T-cell activation is a
feature of both adults and children with
moderate to severe AD. In pediatric
AD, Th2 imbalance is confined to skin
homing/CLAþ T cells and does not
extend to CD8þ T cells, whereas in
adults, Th2 activation extends into
systemic/CLAe CD4þ T cells and CD8þ
T cells (Czarnowicki et al., 2015a).
Consistent with elevated IgE levels in
80% of AD patients (Weidinger and
Novak, 2016), AD blood is character-
ized by a unique peripheral B-cell
signature, and subsets of memory B
cells correlate with clinical AD severity
(Scoring Atopic Dermatitis score/
SCORAD) and IgE levels (Czarnowicki
et al., 2016). In peripheral blood,
several biomarkers were shown to
correlate with disease activity,
including systemic cytokine activation
(Haeck et al., 2011; Hayashida et al.,
2011; Jahnz-Rozyk et al., 2005; Raap
et al., 2012; Waxweiler et al., 2011).
Alarmins (especially IL-33, but also IL-
25 and thymic stromal lymphopoietin)
have recently been shown to drive
the cutaneous expansion of innate
lymphoid cells—particularly innatelymphoid cell-2, producing IL-5 and IL-
13—in AD skin (Salimi et al., 2013;
Soumelis et al., 2002); this recently
described mechanism may play a key
early role in systemic activation related
to AD (Saunders et al., 2016).
AD has been shown to share sus-
ceptibility loci with other immune-
mediated diseases such as psoriasis,
inflammatory bowel disease, and alo-
pecia areata (Ellinghaus et al., 2013;
Weidinger et al., 2013). In a German
cohort study, AD was associated with a
slightly increased risk for rheumatoid
arthritis and inflammatory bowel dis-
ease and a decreased risk for type 1
diabetes (relative risk ¼ 0.72), inde-
pendent of known risk alleles (see
Supplementary Table S1) (Schmitt et al.,
2016). Prominent Th1 and Th17 re-
sponses promoting autoimmunity are
known to be present in inflammatory
bowel disease and rheumatoid arthritis
and are also implicated in the transition
to chronic inflammation in AD (Gittler
et al., 2012). Autoreactivity is most
common in severe and persistent AD
(Tang et al., 2012). In a Taiwanese study
(Wu et al., 2014), AD was associated
with lupus erythematosus (odds ratio
[OR] ¼ 1.94, 95% confidence interval
[CI] ¼ 1.48e2.54) (see Supplementary
Table S1), another disease in which
not only Th1 and Th2 but also Th17
responses may play a pathogenic role
(Martin et al., 2014; Oh et al., 2011).
Associations were more prominent in
individuals younger than 18 years of
age (OR ¼ 3.02, 95% CI ¼ 1.30e7.03)
and in female patients (OR ¼ 2.05,
95% CI ¼ 1.53e2.76) (Wu et al.,
2014). Future studies will need to
identify potential subsets of AD patients
at highest risk and elucidate the mech-
anism underlying these associations.
Infection
The increased association of AD with
more frequent and severe bacterial and
viral infections is a minor diagnostic
criterion (Hanifin and Rajka, 1980).
Staphylococcus aureus is cultured from
up to 90% of AD lesions (Leyden et al.,
1974), and methicillin-resistant
S. aureus predominates in some pa-
tients. Skin microbiome and virome
research has expanded our view on the
role of infections in AD (Belkaid and
Segre, 2014; Kong et al., 2012). Bacte-
rial gene sequencing studies found thatwww.jidonline.org 19
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S. aureus and decreased microbial di-
versity (Kong et al., 2012). Moreover,
AD treatment (including intermittent
bleach baths and anti-inflammatory
medications) decreases S. aureus and
increases microbial diversity (Kong
et al., 2012).
The relative role of S. aureus dys-
biosis as a result versus instigator of AD
is unclear. Dysbiosis (microbial imbal-
ance) may directly affect AD skin
inflammation (Kobayashi et al., 2015).
S. aureus has been shown to induce IL-
4/IL-13 and IL-22 cytokines, promoting
Th2/Th22 inflammation in AD (Brandt
and Sivaprasad, 2011; Niebuhr et al.,
2010) and might even affect systemic
immune deviation such as food al-
lergies (Jones et al., 2016). Experimen-
tally, occurrence of pruritic AD-like
dermatitis in keratinocyte-specific
Adam17-deficient mice depends on
the presence of S. aureus and Coryne-
bacterium bovis (Blaydon et al., 2011;
Kobayashi et al., 2015), suggesting
that bacteria might trigger AD in
humans as well. Further, sodium hypo-
chlorite (bleach) baths are not just
antiseptic but also reduce AD severity
(Huang et al., 2009; Huang et al.,
2011), although perhaps in part by
direct anti-inflammatory effects (Leung
et al., 2013). Increasing microbial di-
versity improves AD severity in mice
(Volz et al., 2014), and Staphylococcus
epidermidis products have anti-
S. aureus activity (Cogen et al., 2010;
Lai et al., 2010; Naik et al., 2012).
There is evidence that cutaneous
application of extracts from nonpatho-
genic bacteria (Vitreoscilla filiformis)
(Gueniche et al., 2008) and even
emollients (Seite et al., 2014) restores
skin dysbiosis and thereby may reduce
AD severity. Greater severity is associ-
ated with higher risk of infection, and
both topical and systemic anti-
inflammatory interventions reduce
staphylococcal colonization (Bath-
Hextall et al., 2010; Boguniewicz and
Leung, 2010).
Eczema herpeticum, a well-
recognized infectious complication,
appears in a subset of patients with se-
vere Th2-polarized AD, greater allergen
sensitization, and more commonly a
history of food allergy and/or asthma
(Beck et al., 2009). Eczema coxsackium
is a newly recognized complication ofJournal of Investigative Dermatology (2017), Volumcoxsackie diseases associated with AD,
which can be confused with eczema
herpeticum (Mathes et al., 2013).
Children with AD also have a higher
prevalence of warts and extracutaneous
infections, including streptococcal
pharyngitis, upper and lower respira-
tory infections, recurrent otitis, chick-
enpox, and urinary tract infections
(Silverberg and Silverberg, 2014) (see
Supplementary Table S1). Recent re-
ports also suggest a relationship be-
tween AD and infective endocarditis
(Fukunaga et al., 2013; Patel and





Analogous to psoriasis, recent studies
have suggested an association between
AD, obesity, and cardiovascular disease
in both adults and pediatric patients. A
meta-analysis of 30 studies showed
higher odds of overweight and/or
obesity in children and adults with AD
in studies from North America and Asia
but not Europe (Zhang and Silverberg,
2015) (see Supplementary Table S1).
In a study using the 2007e2008
National Survey of Children’s Health
with 45,897 U.S. adolescents, an
increased prevalence of overweight
and/or obesity was found in adoles-
cents with AD versus healthy control
subjects (Silverberg and Simpson,
2014) (see Supplementary Table S1).
Increased waist circumference percen-
tiles (85th percentile or greater: OR ¼
3.92, 95% CI, 1.50e10.26) and waist-
to-height ratios (ratio of 0.5 or greater:
OR ¼ 2.22, 95% CI ¼ 1.10e4.50) (see
Supplementary Table S1) have also
been associated with moderate to
severe AD in children (Silverberg et al.,
2015). The recognition by practitioners
of obesity in many patients with psori-
asis, but not with AD, may reflect
the higher overall body mass indexes
among psoriasis versus AD patients
with obesity.
Moderate to severe pediatric AD has
significantly higher systolic (OR ¼
2.94, 95% CI ¼ 1.04e8.36) and dia-
stolic (OR ¼ 3.68, 95% CI ¼
1.19e11.37) blood pressures and
significantly higher odds of systolic
blood pressure at or above the 90th
percentile (OR ¼ 2.06, 95% CI ¼e 1371.09e3.90) (Silverberg et al., 2015) (see
Supplementary Table S1), unrelated to
excess adiposity. Adults with AD have
significantly higher odds of a self-
reported history of hypertension,
adult-onset diabetes, and hypercholes-
terolemia, even after controlling for
body mass index and/or comorbid
allergic disease (Silverberg and
Greenland, 2015) (see Supplementary
Table S1). Cardiovascular risk is
further increased when fatigue and
sleep disturbances are present.
Patients with AD may have poor
health behaviors that increase their
cardiovascular risk. In adults, the odds
are higher for smoking at least 100
cigarettes in their lifetime, currently
smoking, initiating smoking at a
younger age, drinking alcohol, and
having reduced vigorous physical ac-
tivity (Silverberg and Greenland, 2015).
Children with severe AD have less
vigorous physical activity and sports
participation and increased hours of
daily television and/or video game use
(Strom and Silverberg, 2016) (see
Supplementary Table S1). The
increased cardiovascular risk factors in
AD likely play a prominent role in the
development of cardiovascular disease.
Hjuler et al. (2015) found evidence
of increased coronary artery calcium
score in the cardiac computed tomog-
raphy angiography 18-segment model
of the coronary tree, and mild single-
vessel disease, in adults with AD
compared with both healthy subjects
and patients with psoriasis (see
Supplementary Table S1). Patients with
psoriasis, however, have more coronary
stenosis and three-vessel or left main
artery disease compared with patients
with AD. Cardiovascular events have
also been evaluated using the
2005e2006 National Health and
Nutrition Examination Survey and the
2010 and 2012 National Health Inter-
view Surveys. Overall, adults with AD
in all three cohorts had significantly
higher odds of coronary disease,
myocardial infarction, and congestive
heart disease; odds of angina, stroke,
and peripheral vascular disease were
also increased in the National Health
Interview Surveys (Silverberg, 2015)
(see Supplementary Table S1). AD has
been reported to be an independent risk
factor for ischemic stroke in a large
Taiwanese study (Su et al., 2014). After
PM Brunner et al.
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AD had a 1.33-fold increased inci-
dence of ischemic stroke, and adjusted
hazard ratios in patients with mild,
moderate, and severe AD were 1.20,
1.64, and 1.71, respectively (see
Supplementary Table S1). However, the
increased risk of cardiovascular disease
in a Danish cohort was no longer pre-
sent after adjustment for socioeco-
nomic status, smoking, comorbidities,
and medication use (Andersen et al.,
2016) (see Supplementary Table S1).
In addition, nonfatal stroke was signifi-
cantly increased in female U.S.-based
nurses with history of ever having AD
when controlling for age (Drucker
et al., 2016) but not after controlling
for hypertension, hypercholesterolemia,
and diabetes; nonfatal myocardial
infarction was not increased. These
studies suggest that poor health behav-
iors and increased cardiovascular risk
factors are the major drivers of cardio-
vascular disease and events in patients
with AD, rather than systemic inflam-
mation (see Supplementary Table S1).
Longitudinal studies are warranted to
assess the potential burden of cardio-
vascular disease in AD.
Cancer
The relationship between AD and
cancer is complex and remains
controversial. A recent meta-analysis
found small but significantly increased
odds of any lymphoma in AD in cohort
(relative risk ¼ 1.43; 95% CI ¼
1.12e1.81), but not case-control
(OR ¼ 1.18; 95% CI ¼ 0.94e1.47)
studies (Legendre et al., 2015) (see
Supplementary Table S1). AD severity
was a significant risk factor. Although
some studies suggest an association of
cutaneous T-cell lymphoma with AD
(Arellano et al., 2007, 2009) (see
Supplementary Table S1), misdiagnosis
of cutaneous T-cell lymphoma as AD in
many adults may lead to the erroneous
overestimation of the association
(Tennis et al., 2011). The mechanisms
underlying the possible association of
AD and lymphoma are poorly under-
stood, but chronic inflammation,
perhaps driven by genetic factors, may
promote carcinogenesis, and inappro-
priate Th2 skewing might divert im-
munity from tumor-protective Th1
responses (Josephs et al., 2013). Sys-
temic immunosuppressive agents usedto treat moderate to severe AD, such as
cyclosporine and azathioprine, in-
crease the risk of malignancy
(Chockalingam et al., 2015; Simon and
Bieber, 2014). Although a regional
health record database study found an
association between topical calci-
neurin inhibitors and increased risk of
lymphoma (Hui et al., 2009), a nested
case-control study with a cohort of
almost 300,000 AD patients found no
association (Arellano et al., 2007,
2009) (see Supplementary Table S1).
Furthermore, a longitudinal cohort of
7,457 children treated with pimecroli-
mus had no increased malignancy
(Margolis et al., 2015). A recent
consensus report concluded that use of
topical calcineurin inhibitors is effec-
tive and safe, even in infants as young
as 3 months of age, suggesting that
warnings of possible carcinogenicity
and restrictions regarding their use un-
der 2 years of age are no longer justi-
fied (Luger et al., 2015).
In contrast to a possible increased
risk of lymphoma, a meta-analysis
found an inverse association between
AD and acute lymphoblastic leukemia
in six studies and no association with
acute myelogenous leukemia in two
studies (Linabery et al., 2010) (see
Supplementary Table S1). No associa-
tion was found between AD and
bladder cancer (Kim et al., 2000).
Recent systematic reviews showed
either inverse or no association be-
tween AD and pancreatic, brain, and
skin cancers (Deckert et al., 2014).
A prospective adult Dutch cohort
study found an inverse association
between AD and actinic keratosis but
no association with basal cell carci-
noma or squamous cell carcinoma
(Hajdarbegovic et al., 2016). A recent
population-based case-control study
found an inverse association between a
history of allergy and early-onset basal
cell carcinoma but not with squamous
cell carcinoma or melanoma (Cheng
et al., 2015) (see Supplementary
Table S1). Reasons for such inverse as-
sociations between AD and cancer
may include increased immune sur-
veillance and eradication of dysregu-
lated cells by systemic inflammation
(Fu et al., 2008), as well as the reported
IgE-facilitated cross-presentation of
tumor antigens by dendritic cells
(Platzer et al., 2015).Neuropsychiatric disorders
AD is associated with higher rates of
psychological diseases such as depres-
sion, anxiety, suicidal ideation, atten-
tion deficit/hyperactivity disorder, and
autism spectrum disorder (Arima et al.,
2005; Buske-Kirschbaum et al., 2013;
Dalgard et al., 2015; Dieris-Hirche
et al., 2009; Riis et al., 2016; Sanna
et al., 2014; Schmitt et al., 2010; Schut
et al., 2014; Yaghmaie et al., 2013) (see
Supplementary Table S1). Although
most studies do not allow conclusions
on temporal relationships and thus
causality, a longitudinal Taiwanese
study found that the presence of any
atopic disease in early childhood (i.e.,
before 3 years of age) increased the risk
of developing attention deficit/hyper-
activity disorder (hazard ratio ¼ 1.97)
and autism spectrum disorder (hazard
ratio ¼ 3.40) later in life, with
increasing risks with higher numbers of
atopic diseases (Chen et al., 2014). The
individual contribution of AD, howev-
er, was not reported.
The underlying mechanisms of
neuropsychiatric disorders in AD are
still unclear, but associations are
potentially driven by the harmful effects
of AD on quality of life (Chrostowska-
Plak et al., 2013; Senra and
Wollenberg, 2014), unbearable
chronic itch, and sleeplessness
(Weisshaar et al., 2008). Clinical in-
vestigations have associated depres-
sion, anxiety, and autism with elevated
levels of proinflammatory (although not
Th2) cytokines (Kiecolt-Glaser et al.,
2011; Pollak and Yirmiya, 2002;
Zimmerman et al., 2005), which theo-
retically could penetrate the blood-
brain barrier (Yarlagadda et al., 2009)
and modulate behavior and emotions
(Buske-Kirschbaum et al., 2013; Ishiuji
et al., 2009; Raison et al., 2006;
Rosenkranz et al., 2005). Other
chronic health conditions of childhood
also increase the risk of emotional and
behavioral problems, including atten-
tion deficit/hyperactivity disorder
(Blackman et al., 2011).
Itch is central to the burden of AD
and is significantly correlated with
sleeplessness. Itch is also associated
with coping behavior and poor quality
of life in parents of children with AD
(Weisshaar et al., 2008), which should
be monitored when evaluating the
impact of AD treatment (Metz et al.,www.jidonline.org 21
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Itch mechanisms in AD are complex
and involve cutaneous nerves as well as
inflammatory cells and keratinocytes
(Kim, 2012; Suarez et al., 2012). There
is evidence for a direct correlation be-
tween the density of peripheral nerves
and AD severity (Sugiura et al., 1997;
Tominaga et al., 2009). Furthermore,
central mechanisms are speculated to
contribute to central sensitization,
resulting in a loss of inhibitory control
and synaptic recruiting of excitatory
interneurons (Stander et al., 2015;
Suarez et al., 2012).
OUTLOOK
The growing list of potential cutaneous
and systemic AD comorbidities reflects
the increasing appreciation of its high
burden, both on affected individuals
and their families, making the devel-
opment of better interventions even
more urgent. Pathophysiological in-
terconnections are complex, because
infections and allergies often develop
during active disease, but malignancy
or cardiovascular disease may be
related to longstanding chronic inflam-
mation or may even occur years after
disease activity had abated. Although
epidemiologic studies aim to reduce
discernible bias and confounder effects
(Nijsten and Wakkee, 2009; Schmitt
and Weidinger, 2014), statistical asso-
ciations cannot prove causality. As new
treatment approaches for AD are being
developed, monitoring of patients
longitudinally to determine the impact
of these approaches on AD-associated
comorbidities, in addition to skin
manifestations, will likely reveal
mechanisms of disease associations
and result in the development of more
targeted, or even personalized, treat-
ment approaches.
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